Extended trial tests drug for rare childhood liver disease
Disease control
Recruiting now
This study is checking the long-term safety and effectiveness of the drug odevixibat for people with Alagille syndrome (ALGS), a rare genetic disorder that affects the liver and causes severe itching. The drug is already approved to treat itching in infants with ALGS over 12 mont…
Phase: PHASE3 • Sponsor: Albireo, an Ipsen Company • Aim: Disease control
Last updated Apr 02, 2026 02:26 UTC